Novel Pan-Lysyl Oxidase Inhibitor PXS-5505 for Improving Pancreatic Cancer Treatment

Learn about groundbreaking pancreatic cancer research in this 21-minute scientific presentation where Dr. Jessica Chitty and Dr. Thomas Cox discuss their development and validation of PXS-5505, a novel selective and irreversible pan-lysyl oxidase inhibitor. Explore how this small molecule drug enhances chemotherapy effectiveness by targeting the tumor microenvironment, with detailed insights into the combined effects of PXS-5505 and gemcetabine on tumor morphology, behavior, and subject survival rates. Published in Nature Cancer and featured in EACR's Highlights in Cancer Research, discover the experimental results from multiple pre-clinical models that demonstrate the potential of this innovative treatment approach for pancreatic cancer patients.